TAVI without BAV
ProcedureAvoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
NCT Number: NCT01539746
The purpose of this study is to demonstrate that the avoidance of balloon valvuloplasty for predilation of the native aortic valve is associated with a reduction of the composite primary endpoint in TAVI patients with severely impaired left-ventricular ejection fraction (LVEF ≤35%).
Looking for future studies?
Notify Me18 year–100 year
All sexes
Interventional
Not applicable
Department of Medicine II - Cardiology, University Hospital Bonn, Bonn, Germany
Transcatheter aortic valve implantation (TAVI) has evolved as an alternative to surgical aortic valve replacement (SAVR) with now more than 50,000 implantations in patients with symptomatic severe aortic stenosis, who were considered to be at very high or prohibitive operative risk. Before deployment of transcatheter heart valves (THV), current medical practice requires right-ventricular rapid burst pacing (>180 bpm) with induction of a functional cardiac arrest for up to 30 seconds for balloon aortic valvuloplasty (BAV). This step is thought to be necessary to predilate the native aortic valve and to facilitate an accurate positioning of the THV. However, BAV has been shown to have numerous detrimental effects: i) the functional cardiac arrest induced by rapid pacing for BAV leads to transient coronary, cerebral, and renal ischemia. ii) In patients with impaired left ventricular ejection fraction, prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS), which are both associated with a high peri-procedural mortality. iii) BAV has been identified as a major source of embolization of thrombotic and valvular material and increases the risk for coronary obstruction with subsequent myocardial infarction and stroke. iv) the local trauma in the left-ventricular outflow tract caused by BAV contributes to conduction disturbances with the need for permanent pacemaker implantation after TAVI.
A non-randomized pilot study by Grube et al. (JACC Interventions 2011) has recently shown that TAVI without BAV is feasible and safe, since self-expanding THV are able to "dilate" the stenosed aortic valve through the radial forces of the self-expanding nitinol frame, in which the prosthesis is mounted. According to the mentioned study, omitting BAV allows the delivery of the THV in a controlled fashion without hemodynamic compromise of the patient.
Patients with LVEF≤35% will be randomized (like the flip of a coin) to TAVI without BAV (experimental group) or TAVI with BAV for predilation (control group).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
TAVI standard procedure including BAV before valve deployment
Time frame: 30 days after TAVI
Occurrence of all-cause mortality, stroke, non-fatal myocardial infarction, acute kidney injury, or pacemaker implantation at 30 days after TAVI.
Time frame: 6 months, 12 months after TAVI
Time frame: 6 months, 12 months after TAVI
Time frame: 6 months, 12 months after TAVI
Time frame: 6 months, 12 months after TAVI
Time frame: 6 months, 12 months after TAVI
Time frame: 30 days, 6 months, 12 months after TAVI
Time frame: 30 days, 6 months, 12 months after TAVI
Time frame: 30 days, 6 months, 12 months after TAVI
Time frame: 30 days, 6 months, 12 months after TAVI
Time frame: 30 days, 6 months, 12 months after TAVI
Time frame: 30 days, 6 months, 12 months after TAVI
Time frame: 30 days, 6 months, 12 months after TAVI
University Hospital, Bonn
Other
Use of the Self-Expanding Medtronic CoreValve Prosthesis Without Predilation in Patients With Severely IMPaired Left-VentrIcular Ejection Fraction for TAVI Trial - The SIMPLIFy TAVI Trial
Acronym: SIMPLIFy TAVI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06481137
Aortic Stenosis, Aortic Valve Disease
L'Hospitalet de Llobregat, Barcelona, Spain
View Trial DetailsNCT06894550
Altitude, Altitude Sickness
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT06211296
Aortic Stenosis, Aortic Valve Disease
Thousand Oaks, California, United States
View Trial DetailsNCT05035277
Aortic Stenosis, Aortic Valve Disease
Oslo, Norway
View Trial Details